ZA201708601B - Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions - Google Patents

Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions

Info

Publication number
ZA201708601B
ZA201708601B ZA2017/08601A ZA201708601A ZA201708601B ZA 201708601 B ZA201708601 B ZA 201708601B ZA 2017/08601 A ZA2017/08601 A ZA 2017/08601A ZA 201708601 A ZA201708601 A ZA 201708601A ZA 201708601 B ZA201708601 B ZA 201708601B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical compositions
inflammatory conditions
treating ocular
ocular inflammatory
integrin alpha4
Prior art date
Application number
ZA2017/08601A
Other languages
English (en)
Inventor
Achim Hans-Peter Krauss
Original Assignee
Axerovision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axerovision Inc filed Critical Axerovision Inc
Publication of ZA201708601B publication Critical patent/ZA201708601B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA2017/08601A 2015-07-08 2017-12-18 Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions ZA201708601B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562189813P 2015-07-08 2015-07-08
PCT/IB2016/054073 WO2017006272A1 (en) 2015-07-08 2016-07-07 Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions

Publications (1)

Publication Number Publication Date
ZA201708601B true ZA201708601B (en) 2019-05-29

Family

ID=56373100

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/08601A ZA201708601B (en) 2015-07-08 2017-12-18 Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions

Country Status (21)

Country Link
US (3) US10413535B2 (enExample)
EP (1) EP3319639B1 (enExample)
JP (2) JP6752276B2 (enExample)
KR (2) KR102440162B1 (enExample)
CN (1) CN107921136A (enExample)
AU (1) AU2016290197B2 (enExample)
BR (1) BR112018000112A2 (enExample)
CA (1) CA2989522C (enExample)
CL (1) CL2018000057A1 (enExample)
ES (1) ES2835274T3 (enExample)
HK (1) HK1247120A1 (enExample)
IL (2) IL256770B (enExample)
MA (2) MA42016A1 (enExample)
MX (1) MX385229B (enExample)
MY (1) MY187552A (enExample)
PL (1) PL3319639T3 (enExample)
RU (1) RU2018103940A (enExample)
TN (1) TN2017000538A1 (enExample)
UA (1) UA123728C2 (enExample)
WO (1) WO2017006272A1 (enExample)
ZA (1) ZA201708601B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3592334A4 (en) * 2017-03-09 2020-12-16 Allysta Pharmaceuticals, Inc. PEPTIDES FOR DRY ILLNESS
CN110996904A (zh) * 2017-05-19 2020-04-10 奥古根有限公司 眼用组合物及使用方法
CN119462635A (zh) 2018-10-30 2025-02-18 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ, インコーポレイテッド アルファ4β7インテグリンの阻害のための化合物
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ, インコーポレイテッド アルファ4ベータ7インテグリンの阻害のための化合物
CA3145870A1 (en) * 2019-07-26 2021-02-04 Hampar L. Karageozian Peptides for treating non-exudative macular degeneration and other disorders of the eye
KR20220047323A (ko) 2019-08-14 2022-04-15 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물
KR102391198B1 (ko) * 2021-08-27 2022-04-27 한림제약(주) 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828074D0 (en) 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
GB0014892D0 (en) 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
ES2530780T3 (es) * 2005-05-17 2015-03-05 Sarcode Bioscience Inc Composiciones y métodos para el tratamiento de trastornos oculares
TWI435729B (zh) * 2005-11-09 2014-05-01 Combinatorx Inc 治療病症之方法,組合物及套組
US20130217657A1 (en) * 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions

Also Published As

Publication number Publication date
MX385229B (es) 2025-03-14
US20180200240A1 (en) 2018-07-19
PL3319639T3 (pl) 2021-03-08
KR20180041122A (ko) 2018-04-23
WO2017006272A1 (en) 2017-01-12
US20200405703A1 (en) 2020-12-31
IL280827A (en) 2021-04-29
BR112018000112A2 (pt) 2018-09-04
TN2017000538A1 (en) 2019-04-12
CA2989522A1 (en) 2017-01-12
RU2018103940A (ru) 2019-08-08
EP3319639A1 (en) 2018-05-16
KR20220062688A (ko) 2022-05-17
ES2835274T3 (es) 2021-06-22
MA42016A1 (fr) 2018-03-30
HK1247120A1 (zh) 2018-09-21
JP2018521126A (ja) 2018-08-02
US10413535B2 (en) 2019-09-17
AU2016290197A1 (en) 2018-01-04
IL256770B (en) 2021-02-28
US20200000786A1 (en) 2020-01-02
IL256770A (en) 2018-03-29
CN107921136A (zh) 2018-04-17
KR102440162B1 (ko) 2022-09-02
US10751334B2 (en) 2020-08-25
JP6752276B2 (ja) 2020-09-09
MA44935A1 (fr) 2019-08-30
AU2016290197B2 (en) 2021-07-22
CL2018000057A1 (es) 2018-06-22
JP2020121985A (ja) 2020-08-13
CA2989522C (en) 2022-10-18
MY187552A (en) 2021-09-29
EP3319639B1 (en) 2020-11-18
RU2018103940A3 (enExample) 2019-09-03
UA123728C2 (uk) 2021-05-26
MX2017017163A (es) 2018-08-09

Similar Documents

Publication Publication Date Title
ZA201708601B (en) Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions
ZA201802920B (en) Topical pharmaceutical formulations for treating inflammatory¿related conditions
SG10202010157VA (en) Pharmaceutical compositions comprising meloxicam
IL248692B (en) Heterocyclic compounds containing deuterium and their use as imaging agents
GB201400034D0 (en) Pharmaceutical Compositions comprising AZD9291
IL250582B (en) Compositions and methods for early screening of medical components
PL3373973T3 (pl) Kompozycje do oczu
SG11201707117SA (en) Ophthalmic composition
PL3445331T4 (pl) Kompozycje okulistyczne niezawierające środków konserwujących
PL3313370T3 (pl) Okulistyczna kompozycja farmaceutyczna
PL3072503T3 (pl) Kompozycja okulistyczna do ochrony rogówki
IL257167A (en) Antitussive compositions and methods
ZA201707872B (en) Compositions comprising anakinra
SG10202106375UA (en) Pharmaceutical compositions and use thereof
IL254711B (en) History of diazepine-indole and medicinal preparations containing them
PT3160263T (pt) Composições para prevenção de infeções
PL3072529T3 (pl) Kompozycja zawierająca wemurafenib i HPMC-AS
SG11201609762TA (en) Anti-allergic agent, agent for improving allergic diarrhea and pharmaceutical composition
ZA201700064B (en) Pharmaceutical compositions comprising antibacterial agents
ZA201602862B (en) Preservative free pharmaceutical ophthalmic compositions
HRP20220610T8 (hr) Farmaceutski pripravci koji sadrže meloksikam
GB201413538D0 (en) Ophthalmic compositions and uses thereof